Sotagliflozin as a potential treatment for type 2 diabetes mellitus

Expert Opinion on Investigational Drugs

Volumn 24, Issue 12, 2015, Pages 1647-1656

  Cariou, Bertrand ^a,b,c   Charbonnel, Bernard ^c  

^a NANTES UNIVERSITY HOSPITAL   (France)

^b L INSTITUT DU THORAX   (France)

^c UNIVERSITÉ DE NANTES   (France)

Author keywords

intestine; kidney; SGLT1; SGLT2; type 1 diabetes; type 2 diabetes

Indexed keywords

GALACTOSE; GLUCOSE; SODIUM GLUCOSE COTRANSPORTER; SOTAGLIFLOZIN; (2S,3R,4R,5S,6R)-2-(4-CHLORO-3-(4-ETHOXYBENZYL)PHENYL)-6-(METHYLTHIO)TETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; ANTIDIABETIC AGENT; GLYCOSIDE; INSULIN; SODIUM GLUCOSE COTRANSPORTER 1; SODIUM GLUCOSE COTRANSPORTER 2;

ARTICLE; BIOLOGY; CLINICAL EFFECTIVENESS; CLINICAL GENETICS; CONTROLLED CLINICAL TRIAL (TOPIC); DIABETIC PATIENT; DRUG MARKETING; DRUG SAFETY; FAMILIAL RENAL GLUCOSURIA; GLUCOSE GALACTOSE MALABSORPTION; HUMAN; IN VITRO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; MALABSORPTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL DIABETES; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; DIABETES MELLITUS, TYPE 2; HYPOGLYCEMIA; METABOLISM; PATHOPHYSIOLOGY; SECRETION (PROCESS);

ANIMALS; DIABETES MELLITUS, TYPE 2; GLUCOSE; GLYCOSIDES; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; SODIUM-GLUCOSE TRANSPORTER 1; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 84949293188     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2015.1100361     Document Type: Article

References (56)

1. Kahn CR. Insulin action, diabetogenes, and the cause of type II diabetes (Banting Lecture). Diabetes. 1994;43:1066-1084.
2. Saltiel AR, Kahn CR. Insulin signalling and the regulation of glucose and lipid metabolism. Nature. 2001;414:799-806.
3. UK Prospective Diabetes Study Group. UK prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes. 1995;44:1249-1258.
4. Defronzo RA. Banting lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58:773-795.
5. Hasan FM, Alsahli M, Gerich JE. SGLT2 inhibitors in the treatment of type 2 diabetes. Diabetes Res Clin Pract. 2014;104:297-322.
6. Wells RG, Pajor AM, Kanai Y, et al. Cloning of human kidney cDNA with similarity to the sodium-glucose cotransporter. Am J Physiol Renal Fluid Electrolyte Physiol. 1992;263:F459-F465.
7. Santer R, Kinner M, Lassen CL, et al. Molecular analysis of the SGLT2 gene in patients with renal glucosuria. J Am Soc Nephrol. 2003;14:2873-2882.
8. Oku A, Ueta K, Arakawa K, et al. T-1095, an inhibitor of renal Na+-glucose cotransporters, may provide a novel approach to treating diabetes. Diabetes. 1999;48:1794-1800.
9. Ferrannini E, Solini A. SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects. Nat Rev Endocrinol. 2012;8:495-502.
10. Wright EM, Loo DD, Hirayama BA. Biology of human sodium transporters. Physiol Rev. 2011;91:733-794.
11. Hediger MA, Coady M, Ikeda T, et al. Expression cloning and cDNA sequencing of the Na+/glucose co-transporter. Nature. 1987;330:379-381.
12. Wright EM, Hirayama BA, Loo DD. Active sugar transport in health and disease. J Intern Med. 2007;1:32-43.
13. Stumpel F, Burcelin R, Jungermann K, et al. Normal kinetics of intestinal glucose absorption in the absence of GLUT2: evidence for a transport pathway requiring glucose phosphorylation and transfer into the endoplasmic reticulum. Proc Natl Acad Sci USA. 2001;98:11330-11335.
14. Santer R, Groth S, Kinner M, et al. The mutation spectrum of the facilitative glucose transporter gene SLC2A2 (GLUT2) in patients with Fanconi-Bickel syndrome. Hum Genet. 2002;110:21-29.
15. Dyer J, Wood IS, Palejwala A, et al. Expression of monosaccharide transporters in intestine of diabetic humans. Am J Physiol Gastrointest Liver Physiol. 2002;282:G241-248.
16. Calado J, Sznajer Y, Metzger D, et al. Twenty-one additional cases of familial renal glucosuria: absence of gentic heterogeneity, high prevalence of private mutations and further evidence of volume depletion. Nephrol Dial Transplant. 2008;23:3874-3879.
17. Scholl-Burgi S, Santer R, Ehrich JH. Longterm outcome of renal glucosuria type 0: the original patient and his natural history. Nephrol Dial Transplant. 2004;19:2394-2396.
18. Lindquist B, Meeuwisse GW. Chronic diarrhoea caused by monosaccharide malabsorption. Acta Paediatr. 1962;51:674-685.
19. Turk E, Zabel B, Mundlos S, et al. Glucose/galactose malabsorption caused by a defect in the NA+/glucose cotransporter. Nature. 1991;350:354-356.
20. Xin B, Wang H. Multiple sequence variations in SLC5A1 gene are associated with glucose-galactose malabsorption in a large cohort of old order Amish. Clin Genet. 2011;79:86-91.
21. Powell DR, DaCosta CM, Gay J, et al. Improved glycemic control in mice lacking Sglt1 and Sglt2. Am J Physiol Endocrinol Metab. 2013;304:E117-E130.
22. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centered approach. Update to a position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2015;58:429-442.
23. Charbonnel B, Cariou B. Pharmacological management of type 2 diabetes: the potential of incretin-based therapies. Diabetes Obes Metab. 2011;13:99-117.
24. Tahrani AA, Barnett AH, Bailey CJ. SGLT inhibitors in management of diabetes. Lancet Diabetes Endocrinol. 2013;1:140-151.
25. Taylor SI, Blau JE, Rother KI. Possible adverse effects of SGLT2 inhibitors on bone. Lancet Diabetes Endocrinol. 2015;3:8-10.
26. Shibazaki T, Tomae M, Ishikawa-Takemura Y, et al. KGA-2727, a novel selective inhibitor of a high-affinity sodium glucose cotransporter (SGLT1), exhibits antidiabetic efficacy in rodent models. J Pharmacol Exp Ther. 2012;342:288-296.
27. Goodwin NC, Mabon R, Harrison BA, et al. Novel L-xylose derivatives as selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes. J Med Chem. 2009;52:6201-6204.
28. Lapuerta P, Zambrowicz B, Strumph P, et al. Development of sotagliflozin, a dual sodiumdependent glucose transporter 1/2 inhibitor. Diab Vasc Dis Res. 2015;12:101-110.
29. Zambrowicz BP, Turner CA, Sands AT. Predicting drug efficacy: knockouts model pipeline drugs of the pharmaceutical industry. Curr Opin Pharmacol. 2003;3:563-570.
30. Powell DR, Smith M, Greer J, et al. LX4211 increases serum glucagon-like peptide 1 and peptide YY levels by reducing sodium/glucose cotransporter 1 (SGLT1)-mediated absorption of intestinal glucose. J Pharmacol Exp Ther. 2013;345:250-259.
31. Powell DR, DaCosta C, Smith M, et al. Effect of LX4211 on glucose homeostasis and body composition in preclinical models. J Pharmacol Exp Ther. 2014;350:232-242.
32. Powell DR, Doree D, Jeter-Jones S, et al. Sotagliflozin improves glycemic control in nonobese diabetes-prone mice with type 1 diabetes. Diabetes Metab Syndr Obes. 2015;8:121-127.
33. Zambrowicz B, Ogbaa I, Frazier K, et al. Effects of LX4211, a dual sodium-dependent glucose cotransporters 1 and 2 inhibitor, on postprandial glucose, insulin, glucagon-like peptide 1, and peptide tyrosine tyrosine in a dose-timing study in healthy subjects. Clin Ther. 2013;35:1162-1173.
34. Komoroski B, Vacchharajani N, Boulton D, et al. Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin Pharmacol Ther. 2009;85:520-526.
35. Sha S, Divineni D, Ghosh A, et al. Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects. Diabetes Obes Metab. 2011;13:669-672.
36. Sarashina A, Koiwai K, Seman LJ, et al. Safety, tolerability, pharmacokinetics and pharmacodynamics of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in healthy Japanese subjects. Drug Metab Pharmacokinet. 2013;28:213-219.
37. Zambrowicz B, Freiman J, Brown PM, et al. LX2411, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial. Clin Pharmacol Ther. 2012;92:158-169.
38. Zambrowicz B, Ding ZM, Ogbaa I, et al. Effects of LX4211, a dual SGLT1/SGLT2 inhibitor, plus sitagliptin on postprandial active GLP-1 and glycemic control in type 2 diabetes. Clin Ther. 2013;35:273-285.
39. Rosenstock J, Cefalu WT, Lapuerta B, et al. Greater dose-ranging effects on A1C levels than on glucosuria with LX4211, a dual inhibitor of SGLT1 and SGLT2, in patients with type 2 diabetes on metformin monotherapy. Diabetes Care. 2015;38:431-438.
40. Yale JF, Bakris G, Cariou B, et al. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab. 2014;16:1016-1027.
41. Zambrowicz B, Lapuerta P, Strumph P, et al. LX4211 therapy reduces postprandial glucose levels in patients with type 2 diabetes mellitus and renal impairment despite low urinary glucose excretion. Clin Ther. 2015;37:71-82.
42. Henry RR, Rosentstock J, Edelman S, et al. Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study. Diabetes Care. 2015;38:412-419.
43. Pieber TR, Famulla S, Eilbracht J, et al. Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4-week, randomized, placebo-controlled trial (EASE-1). Diabetes Obes Metab. 2015. DOI:10.1111/dom.12494. [Epub ahead of print]
44. Sands AT, Zambrowicz BP, Rosenstock J, et al. Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, as adjunct therapy to insulin in type 1 diabetes. Diabetes Care. 2015;38:1181-1188.
45. Taylor SI, Blau JE, Rother KI. Perspective: SGLT2 inhibitors may predispose to ketoacidosis. J Clin Endocrinol Metab. 2015 Jun 18:jc20151884. [Epub ahead of print]
46. Thomas MC, Jandeleit-Dahm K, Bonnet F. Beyond glycosuria: exploring the intrarenal effects of SGLT-2 inhibition in diabetes. Diabetes Metab. 2014;40:S17-22.
47. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. New Engl J Med. 2015. DOI:10.1056/NEJMoa1504720. [Epub ahead of print]
48. Neal B, Perkovic V, de Zeeuw D, et al. Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS) - a randomized placebo controlled trial. Am Heart J. 2013;166:217-223.
49. FDA Drug Safety Communication: FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood. FDA safety announcement [Internet]. 2015 [cited 2015 May 15]. http://www.fda.gov/Drugs/DrugSafety/ucm446845.htm
50. Erondu N, Desai M, Ways K, et al. Diabetic ketoacidosis and related events in the canagliflozin type 2 diabetes clinical program. Diabetes Care. 2015 Jul 22. pii: dc151251. [Epub ahead of print]
51. Rosenstock J, Aggarwal N, Polidori D, et al. Canagliflozin DIA 2001 study group/Dose-ranging effects of canagliflozin, a sodium glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. Diabetes Care. 2012;35:1232-1238.
52. List JF, Woo V, Morales E, et al. Sodiumglucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care. 2009;32:650-657.
53. Ferraninni E, Seman L, Seewaldt-Becker E, et al. Phase IIb, randomized, placebocontrolled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes. Diabetes Obes Metab. 2013;15:721-728.
54. Bonner C, Kerr-Conte J, Gmyr V, et al. Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. Nat Med. 2015;21:512-517.
55. Merovci A, Solis-Herrera C, Daniele G, et al. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest. 2014;124:509-514.
56. Cohen JJ, Berglund F, Lotspeich WD. Renal tubular absorption of acetoacetate, inorganic sulfate and inorganic phosphate in the dog as affected by glucose and phlorizin. Am J Physiol. 1956;184:91-96.